tetano
Editor, Senior Moderator
J Med Virol
. 2021 Jul 7.
doi: 10.1002/jmv.27184. Online ahead of print.
The Role of Angiopoietin-2 and Surfactant Protein-D Levels in SARS-CoV-2-related lung injury: A prospective, observational, cohort study
Handan Alay[SUP] 1 [/SUP], Esra Laloglu[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease-2019 (COVID-19) is a respiratory disease whose clinical manifestation ranges from asymptomatic to severe respiratory failure. The purpose of this study was to investigate the place of serum surfactant-D (SP-D) and angiopoetin-2 (Ang-2) levels in predicting severity of disease in patients diagnosed with COVID-19.
Method: Sixty-four patients diagnosed with COVID-19 between September 2020 and February 2021, 50 patients diagnosed with community-acquired pneumonia (CAP) and a 50-member healthy control group were included in the study. Plasma samples and clinical data were collected within 72 h after admission, during hospital stay. Serum SP-D and Ang-2 concentrations were measured using the enzyme-linked immunosorbent assay.
Results: SP-D and Ang-2 levels were significantly higher in the mild-moderate pneumonia and severe/critical patient groups compared to the asymptomatic and non-complicated COVID-19 patients (p<0.001 for all groups). Serum SP-D and Ang-2 levels of severe-critical COVID-19 patients were significantly higher than CAP patients (p<0.001). Powerful correlation was present between clinical severity of COVID-19 and SP-D and Ang-2 levels (r=0.885 p<0.001 and r=0.913 p<0.001, respectively). Cut-off values of 37.7 ng/ml (AUC=0.763, p<0.001, 95% CI 0.667-0.860) for SP-D and 4208.3 pg/ml (AUC=0.659, p=0.004, 95% CI 0.554-0.763) for Ang-2 were identified as predictors of COVID-19 disease at ROC curve analysis.
Conclusion: SP-D and Ang-2 are predictive factors in differentiating COVID-19 patients and determining severity of disease. These data may be important for the initiation of treatment in the early stage of the disease in patients with COVID-19. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; angiopoetin-2; lung injury; serum surfaktan-D.
. 2021 Jul 7.
doi: 10.1002/jmv.27184. Online ahead of print.
The Role of Angiopoietin-2 and Surfactant Protein-D Levels in SARS-CoV-2-related lung injury: A prospective, observational, cohort study
Handan Alay[SUP] 1 [/SUP], Esra Laloglu[SUP] 2 [/SUP]
Affiliations
- PMID: 34232533
- DOI: 10.1002/jmv.27184
Abstract
Introduction: Coronavirus disease-2019 (COVID-19) is a respiratory disease whose clinical manifestation ranges from asymptomatic to severe respiratory failure. The purpose of this study was to investigate the place of serum surfactant-D (SP-D) and angiopoetin-2 (Ang-2) levels in predicting severity of disease in patients diagnosed with COVID-19.
Method: Sixty-four patients diagnosed with COVID-19 between September 2020 and February 2021, 50 patients diagnosed with community-acquired pneumonia (CAP) and a 50-member healthy control group were included in the study. Plasma samples and clinical data were collected within 72 h after admission, during hospital stay. Serum SP-D and Ang-2 concentrations were measured using the enzyme-linked immunosorbent assay.
Results: SP-D and Ang-2 levels were significantly higher in the mild-moderate pneumonia and severe/critical patient groups compared to the asymptomatic and non-complicated COVID-19 patients (p<0.001 for all groups). Serum SP-D and Ang-2 levels of severe-critical COVID-19 patients were significantly higher than CAP patients (p<0.001). Powerful correlation was present between clinical severity of COVID-19 and SP-D and Ang-2 levels (r=0.885 p<0.001 and r=0.913 p<0.001, respectively). Cut-off values of 37.7 ng/ml (AUC=0.763, p<0.001, 95% CI 0.667-0.860) for SP-D and 4208.3 pg/ml (AUC=0.659, p=0.004, 95% CI 0.554-0.763) for Ang-2 were identified as predictors of COVID-19 disease at ROC curve analysis.
Conclusion: SP-D and Ang-2 are predictive factors in differentiating COVID-19 patients and determining severity of disease. These data may be important for the initiation of treatment in the early stage of the disease in patients with COVID-19. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; angiopoetin-2; lung injury; serum surfaktan-D.